Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03735433 · ClinicalTrials.gov registry record · Phase 4
The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
A Phase 4 study, sponsored by Ohio State University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 152
- Enrollment target
NCT03735433: Clinical Trial Phase 4 study, sponsored by Ohio State University.
NCT03735433 is a Phase 4 study that was terminated before completion, run by Ohio State University. The registered enrollment target is 152 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03735433, a Phase 4 study, was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 152 participants
- Enrollment target
Study Summary
Low dose aspirin (LDA) is used for preeclampsia (PE) prevention in high risk women, but the precise mechanism and optimal dose is not known. Evidence in the non-obstetric literature suggests AR may be more common among patients with a high body mass index (BMI). Recent unpublished data showed that LDA substantially lowers TxB2 levels regardless of BMI, but rates of complete platelet inhibition are lower in women with BMI ≥40. This data suggests that higher doses of ASA may be necessary in obese women. Therefore we plan determine if use of 162mg compared to the traditional 81mg ASA decreased rates of preeclampsia in women considered high risk for developing preclampsia.
Primary Outcome
by acog definitions
Interventions
- DRUG 162mg aspirin dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 4 |
Why NCT03735433 stopped before completion
NCT03735433 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 1 intervention - of which 162mg aspirin dose is the first listed.
NCT03735433 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03735433 about?
NCT03735433 is a clinical study titled "The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia". Low dose aspirin (LDA) is used for preeclampsia (PE) prevention in high risk women, but the precise mechanism and optimal dose is not known. Evidence in the non-obstetric literature suggests AR may be more common among patients with a high body mass index (BMI). Recent unpublished data showed that L...
What is the current status of trial NCT03735433?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 152 participants. The study started on 2019-01-15. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT03735433?
The interventions under investigation include: 162mg aspirin dose (DRUG).
Who is sponsoring clinical trial NCT03735433?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03735433's enrollment target sits among peer trials
152 530th of 2000 higher than 1,468 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI